ORKA Oruka Therapeutics, Inc.

NASDAQ
$84.46

Oruka Therapeutics, Inc. (ORKA) is expected to report earnings on November 16, 2026, after the market close. The consensus earnings estimate is a loss of $0.68 per share, and the stock has had a Post-Earnings Announcement Drift (PEAD) of -12.5% since its last earnings release on August 10, 2026.

Oruka Therapeutics Missed Consensus Estimates
Monday, August 10, 2026 · 7:03 AM ET
Earnings Date
3rd Quarter, Sep 2026
Nov 16
Monday · After Close
Earnings Whisper
-
vs ($0.68)
Volatility
Enter your expectations below to reveal the current volatility.
Trend Analysis
Expectation
Earnings
Price action
Signals
Score
Sentiment
Grade
Life Cycle
Call Analysis
Earnings-AVWAP $98.51

Sign in or subscribe to unlock sentiment, short interest, and technical indicators.

About Oruka Therapeutics, Inc.

Oruka Therapeutics is developing novel biologics designed to set a new standard for the treatment of chronic skin diseases.

Sector

Healthcare

Industry

Biotechnology

Held By 2 ETFs, by dollar flow

Charts powered in part by Lightweight Charts™ by TradingView.